The Diabetes Prevention Program Outcomes Study AD/ADRD Project
Launched by MARINELLA TEMPROSA · Jan 19, 2023
Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
DPPOS AD/ADRD focuses on one of the most important, complex questions in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) research: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for cognitive impairment and represent a large fraction of the United States (US) population? Despite knowledge that persons with PreD and T2D are a high-risk group for cognitive decline, mild cognitive impairment (MCI), and dementia, the risk factors, mechanisms, and neuropathology...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All surviving participants originally randomized in the Diabetes Prevention Program
- • For Brain Imaging subcohort, only participants aged 55 years and older and those without contraindication to MRI will be included. Contraindications to MRI include the inability to lie flat, claustrophobia, and the presence of indwelling metallic objects, medical or non-medical, that are not 3T MRI compatible.
- Exclusion Criteria:
- • -
About Marinella Temprosa
Marinella Temprosa is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on various therapeutic areas, the organization collaborates with healthcare professionals, research institutions, and regulatory bodies to ensure the highest standards of ethical conduct and data integrity. Marinella Temprosa emphasizes transparency and patient safety in all its clinical trials, striving to contribute meaningful insights that enhance treatment options and foster advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Boston, Massachusetts, United States
New York, New York, United States
New York, New York, United States
Chicago, Illinois, United States
Pittsburgh, Pennsylvania, United States
Bronx, New York, United States
Boston, Massachusetts, United States
Miami, Florida, United States
Indianapolis, Indiana, United States
Albuquerque, New Mexico, United States
Memphis, Tennessee, United States
Honolulu, Hawaii, United States
Saint Louis, Missouri, United States
Aurora, Colorado, United States
Philadelphia, Pennsylvania, United States
San Antonio, Texas, United States
Lutherville, Maryland, United States
Washington, District Of Columbia, United States
Baton Rouge, Louisiana, United States
Phoenix, Arizona, United States
Alhambra, California, United States
San Diego, California, United States
Washington, District Of Columbia, United States
Rockville, Maryland, United States
Shiprock, New Mexico, United States
Zuni, New Mexico, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Jose Luchsinger
Principal Investigator
Columbia University
David Nathan
Study Chair
Massachusetts General Hospital
Marinell Temprosa
Principal Investigator
George Washington University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials